ClinicalTrials.gg
TerminatedNCT03325439Updated Apr 8, 2024Results posted

A Study to Test the Pharmacokinetics, Efficacy, and Safety of Brivaracetam in Newborns With Repeated Electroencephalographic Seizures

A Phase 3 interventional study of Brivaracetam (BRV) intravenous (iv) and Brivaracetam (BRV) oral in Electroencephalographic Neonatal Seizures, sponsored by UCB Biopharma SRL. Terminated at 12 sites in 7 countries. Open to participants aged 1 Day to 28 Days. Per ClinicalTrials.gov, last updated 2024-04-08.

Sponsored by UCB Biopharma SRL (part of UCB S.A.) · Phase 3, Interventional, and Treatment

Why this study was terminated
Terminated (The study stopped prematurely due to enrolment challenges, the termination was not linked to any safety issues.)

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
9
Allocation
Not applicable
Ages
1 Day to 28 Days
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 34 studies testing brivaracetam in Epilepsy — 2 open to participants now, 2 under way, 1 of them phase 3. brivaracetam · Epilepsy.

Enrollment
33rd of 34
9 · median 94
Started
2019
with 1 other
Phase 3
21 of 34
1 open now
Registered
24th of 34
by date
Lead sponsor
7 of 34
UCB Biopharma SRL

Among the 34 studies testing brivaracetam in Epilepsy, this one is the 33rd largest by enrollment, is one of 2 that started in 2019, is one of 21 in phase 3, and was the 24th registered.

Epilepsy

1,848 studies on the registry are indexed under Epilepsy; 419 are open to participants now.

Browse Epilepsy studies →

Open to participants now

2 of the 34 studies testing brivaracetam in Epilepsy are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About brivaracetam

brivaracetam: first FDA approval 2016 (BRIVIACT), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 282 Epilepsy studies recruiting now, 112 (40%) set no upper age limit and 147 (52%) stop at 75 or younger; 139 take children under 18; 55 take healthy volunteers.

This study: 1 Day to 28 Days · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies testing brivaracetam in Epilepsy, or all of them as a file.
02

Study summary

The purpose of the study is to evaluate the pharmacokinetics (PK) of brivaracetam (BRV) in neonates who have seizures that are not adequately controlled with previous antiepileptic drug (AED) treatment, and to identify the optimal BRV dose (Exploratory Cohort) for the treatment of subjects enrolled into the Confirmatory Cohorts of this study.

03

Conditions studied

  • Electroencephalographic Neonatal Seizures

Browse trials for

Keywords

  • Electroencephalographic neonatal seizures
  • Brivaracetam
  • Epilepsy
  • ENS
  • Newborns
  • Pharmacokinetic
04

Who can participate

Ages eligible
1 Day to 28 Days
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Confirmation on video-electroencephalography (VEEG) of >= 2 minutes of cumulative electroencephalographic neonatal seizures (ENS), or >=3 identifiable ENS prior to entering the Evaluation Period, despite receiving previous antiepileptic drug treatment for the treatment of electroencephalographic seizures. The occurrence of ENS during an up to 1-hour period must be confirmed either by the local or central VEEG reader prior to drug administration. Preferably, the central VEEG reader should confirm the required ENS
  • Subject is male or female and must be at least 34 weeks of corrected gestational age (CGA). In addition, term neonates up to 27 days of postnatal age (PNA) and preterm neonates up to 40 weeks of CGA and 27 days of PNA can be enrolled
  • Subject weighs at least 2.3 kg at the time of enrollment
  • Subjects with or without concomitant hypothermia treatment

Exclusion criteria

Exclusion Criteria:

Subjects are not permitted to be enrolled in the study if any of the following criteria are met:

  • Subject receiving antiepileptic drug (AED) treatment other than phenobarbital, midazolam, phenytoin, levetiracetam (≤60 mg/kg/day), or lidocaine for the treatment of seizures prior to or at the time of enrollment (Confirmatory Cohorts only)
  • Subject with seizures responding to any of the following: previous AED treatment immediately prior to BRV treatment, pyridoxine treatment, or correction of metabolic disturbances (hypoglycemia, hypomagnesemia, or hypocalcemia)
  • Subject requires extra corporeal membrane oxygenation
  • Subject has seizures related to prenatal maternal drug use or drug withdrawal
  • Subject has known severe disturbance of hemostasis, as assessed by the Investigator
  • Subject has a poor prognosis for survival, as judged by the Investigator
  • Subject has 2x (ULN) of any of the following: (AST), alanine aminotransferase (ALT), and alkaline phosphatase (ALP), with the following exception:

For subjects with perinatal asphyxia, elevation of AST, ALT or ALP \<5x ULN is acceptable, if initial and peak elevation of liver function tests (LFTs) occurs within 5 days after birth, and the time course of LFT elevation is compatible with hepatic injury due to perinatal asphyxia. The determination of ULN will be based on the subject's gestational age (GA) and the site's normal range values for the respective GA

  • Subject has direct (conjugated) levels >2 mg/dL
  • Subject requiring or expected to require phototherapy or exchange transfusion due to elevated bilirubin
  • Subject with rapidly increasing bilirubin that may preclude the subject from inclusion in the study at the discretion of the Investigator
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
9 participants (actual)

Study arms

  • Experimental
    Brivaracetam (BRV)

    Exploratory Cohort and Confirmatory Cohorts

    Drug: Brivaracetam (BRV) intravenous (iv) · Drug: Brivaracetam (BRV) oral

Interventions

  • Exploratory Cohort: Subjects will be dosed with BRV (0.5 mg/kg twice daily (bid)) according to the sites standard procedures. Treatment with 1 or more of the following antiepileptic drugs (AEDs): phenobarbital (PB), midazolam (MDZ), phenytoin (PHT), levetiracetam (LEV), or lidocaine (LDC) (first-line, second-line, or subsequent treatment) will continue in parallel with BRV treatment. Confirmatory Cohort: For subjects who enter the Confirmatory Cohorts, for the strength of BRV 1 mg/kg bid (2 mg/kg/day) has been determined based on the Pharmacokinetic (PK) findings of the Exploratory Cohort. Based on further monitoring of PK and safety findings dosing may be adjusted as new data are available. Administration of BRV is proposed as approximately 15-minute intravenous (iv) infusions. Treatment with previous antiepileptic drugs is permitted to continue if the subject is on a stable dose from 1 hour prior to initiation of the BRV treatment.

    Also known as: Briviact

  • Subjects can switch from intravenous (iv) to oral brivaracetam (BRV) at any time during the BRV Extension Period

    Also known as: Briviact

06

What researchers measure

Primary outcomes

  1. Plasma Concentration of Brivaracetam (BRV) Following First Dose on Day 1

    Pharmacokinetic blood samples were taken 0.5 to 1 hour, 2 to 4 hours, and 8 to 12 hours after the BRV infusion on Day 1 to determine the BRV plasma concentration.

    Time frame: Pharmacokinetic blood samples were taken 0.5 to 1 hour, 2 to 4 hours, and 8 to 12 hours after the BRV infusion on Day 1

Secondary outcomes

  1. Percentage of Responders to BRV Treatment From Baseline to 3 Hours After the Initial BRV Treatment

    A BRV responder was defined as a participant who achieved the following reduction in seizure burden (electroencephalographic neonatal seizures (ENS) in minutes per hour) without need for rescue medication, compared to the seizure burden measured during the Baseline Period immediately prior to BRV administration, evaluated for a 2-hour period starting 1 hour after the start of initial BRV treatment: At least 80% reduction in nonsevere seizure burden (Nonsevere seizure burden is defined as \<=50% seizure activity on video-electroencephalography (VEEG) in all 30-minute timespans), OR At least 50 % reduction in severe seizure burden (Severe seizure burden is defined as \>50 % seizure activity on VEEG in any 30-minute timespan). Timespans of 30 minutes refer to the following intervals within the 2-hour period: 0 to \<= 30 minutes, \> 30 to \<= 60 minutes, \>60 to \<= 90 minutes, and \>90 to \<= 120 minutes.

    Time frame: From Baseline to 3 hours after the initial BRV treatment

  2. Percentage of Participants With at Least 80% Reduction in Nonsevere Seizure Burden From Baseline to 3 Hours After the Initial BRV Treatment

    Nonsevere seizure burden was defined as \<=50% seizure activity on VEEG in all 30-minute timespans. Seizure burden was measured during the Baseline Period immediately prior to BRV administration and evaluated for a 2-hour period starting 1 hour after the start of initial BRV. Timespans of 30 minutes refer to the following intervals within the 2-hour period: 0 to \<= 30 minutes, \> 30 to \<= 60 minutes, \>60 to \<= 90 minutes, and \>90 to \<= 120 minutes.

    Time frame: From Baseline to 3 hours after the initial BRV treatment

  3. Percentage of Participants With at Least 50% Reduction in Severe Seizure Burden From Baseline to 3 Hours After the Initial BRV Treatment

    Severe seizure burden was defined as \>50% seizure activity on VEEG in any 30-minute timespan. Seizure burden was measured during the Baseline Period immediately prior to BRV administration and evaluated for a 2-hour period starting 1 hour after the start of initial BRV. Timespans of 30 minutes refer to the following intervals within the 2-hour period: 0 to \<= 30 minutes, \> 30 to \<= 60 minutes, \>60 to \<= 90 minutes, and \>90 to \<= 120 minutes.

    Time frame: From Baseline to 3 hours after the initial BRV treatment

  4. Absolute Change in Average Seizure Burden Measured by Continuous Video-electroencephalography (VEEG) From Baseline to the End of the 96-hour Evaluation Period

    Seizure burden was measured by continuous video-electroencephalography (VEEG). Baseline seizure burden is defined as seizure burden measured on the continuous VEEG (total electroencephalographic neonatal seizures (ENS) in minutes per hour) during a period of up to 1 hour immediately prior to the first administration of study drug.

    Time frame: From Baseline to the end of the 96-hour Evaluation Period

  5. Percentage Change in Average Seizure Burden Measured by Continuous VEEG From Baseline to the End of the 96-hour Evaluation Period

    Seizure burden was measured by continuous video-electroencephalography (VEEG). Baseline seizure burden was defined as seizure burden measured on the continuous VEEG (total electroencephalographic neonatal seizures (ENS) in minutes per hour) during a period of up to 1 hour immediately prior to the first administration of study drug.

    Time frame: From Baseline to the end of the 96-hour Evaluation Period

  6. Percentage of BRV Responders at the End of the 96-hour Evaluation Period

    A BRV responder was defined as a participant who achieves the following reduction in seizure burden (electroencephalographic neonatal seizures (ENS) in minutes per hour) without need for rescue medication, compared to the seizure burden measured during the Baseline Period immediately prior to BRV administration, evaluated for a 2-hour period starting 1 hour after the start of initial BRV treatment: At least 80% reduction in nonsevere seizure burden (Nonsevere seizure burden is defined as \<=50% seizure activity on VEEG in all 30-minute timespans), OR At least 50% reduction in severe seizure burden (Severe seizure burden is defined as \>50% seizure activity on VEEG in any 30-minute timespan).

    Time frame: From Baseline to the end of the 96-hour Evaluation Period

  7. Percentage of Participants Who Are Seizure-free at 24 Hours Following the Start of Initial BRV Treatment, Categorized by Subjects With Nonsevere or Severe Seizure Burden at Baseline

    Seizure freedom is defined as 100 % reduction in seizure burden from Baseline.

    Time frame: From Baseline to 24 hours after the initial BRV treatment

  8. Time to Reduction in Seizure Burden for BRV Responders

    A BRV responder was defined as a participant who achieves the following reduction in seizure burden (electroencephalographic neonatal seizures (ENS) in minutes per hour) without need for rescue medication, compared to the seizure burden measured during the Baseline Period immediately prior to BRV administration, evaluated for a 2-hour period starting 1 hour after the start of initial BRV treatment: At least 80% reduction in nonsevere seizure burden (Nonsevere seizure burden is defined as \<=50% seizure activity on VEEG in all 30-minute timespans), OR At least 50% reduction in severe seizure burden (Severe seizure burden is defined as \>50% seizure activity on VEEG in any 30-minute timespan).

    Time frame: From Baseline to the first timepoint when BRV responder criteria are met (up to 96-hour Evaluation Period)

  9. Percentage of Participants With Seizure Freedom at the End of the Down-Titration Period

    Seizure freedom was defined as 100% reduction in seizure burden from Baseline.

    Time frame: From Baseline to the end of the Down-Titration Period (up to 97 days)

  10. Percentage of Participants With at Least 50% Reduction in Electroencephalographic Neonatal Seizures (ENS) Frequency Per Hour From Baseline to the End of the 96-hour Evaluation Period

    For this study, an ENS was defined as an EEG seizure lasting for at least 10 seconds on VEEG. Baseline seizure burden was defined as seizure burden measured on the continuous VEEG (total ENS in minutes per hour) during a period of up to 1 hour immediately prior to the first administration of study drug.

    Time frame: From Baseline to the end of the 96-hour Evaluation Period

  11. Percentage of Participants Who Are Seizure-free by Time Interval Over the 96-hour Evaluation Period Following the Start of the Initial BRV Treatment

    Seizure freedom was defined as 100% reduction in seizure burden from Baseline.

    Time frame: From 3 hours following the start of the initial BRV treatment to the end of the 96-hour Evaluation Period

  12. Absolute Difference in Clinical Seizures at the End of the 24-hour Evaluation Period From Baseline for Neonates With Motor Seizures at the Time of Inclusion

    Seizures was measured by continuous video-electroencephalography (VEEG).

    Time frame: From Baseline to the end of the 24-hour Evaluation Period

  13. Percent Difference in Clinical Seizures at the End of the 24-hour Evaluation Period From Baseline for Neonates With Motor Seizures at the Time of Inclusion

    Seizures was measured by continuous video-electroencephalography (VEEG).

    Time frame: From Baseline to the end of the 24-hour Evaluation Period

  14. Percentage of Participants With Adverse Events (AEs) as Reported by the Investigator

    An adverse event (AE) was any untoward medical occurrence in a patient or clinical investigation study participant administered a pharmaceutical product that did not necessarily have a causal relationship with this treatment.

    Time frame: Adverse Events were collected from Screening Period until the Safety Follow-Up Visit (up to Day 75)

07

Results

Posted Jan 16, 2024
Limitations and caveats
No eligible study participants were enrolled in the Confirmatory Cohorts. The study stopped prematurely due to enrolment challenges, the termination was not linked to any safety issues.

Participant flow

The study started to enroll participants in May 2019 and concluded in May 2021.

Participant flow — Overall Study
MilestoneExploratory Cohort
Started9
Treated6
Completed6
Not completed3
Withdrew: Ineligibility3

Outcome measures

PrimaryPlasma Concentration of Brivaracetam (BRV) Following First Dose on Day 1

Pharmacokinetic blood samples were taken 0.5 to 1 hour, 2 to 4 hours, and 8 to 12 hours after the BRV infusion on Day 1 to determine the BRV plasma concentration.

Time frame:
Pharmacokinetic blood samples were taken 0.5 to 1 hour, 2 to 4 hours, and 8 to 12 hours after the BRV infusion on Day 1
Reported as:
Geometric mean · nanograms per milliliter (ng/mL)
Plasma Concentration of Brivaracetam (BRV) Following First Dose on Day 1
nanograms per milliliter (ng/mL)Exploratory Cohort
0.5-1 hour534.2 ± 15.4
2-4 hours500.1 ± 28.2
8-12 hours342.7 ± 13.2
SecondaryPercentage of Responders to BRV Treatment From Baseline to 3 Hours After the Initial BRV Treatment

A BRV responder was defined as a participant who achieved the following reduction in seizure burden (electroencephalographic neonatal seizures (ENS) in minutes per hour) without need for rescue medication, compared to the seizure burden measured during the Baseline Period immediately prior to BRV administration, evaluated for a 2-hour period starting 1 hour after the start of initial BRV treatment: At least 80% reduction in nonsevere seizure burden (Nonsevere seizure burden is defined as \<=50% seizure activity on video-electroencephalography (VEEG) in all 30-minute timespans), OR At least 50 % reduction in severe seizure burden (Severe seizure burden is defined as \>50 % seizure activity on VEEG in any 30-minute timespan). Timespans of 30 minutes refer to the following intervals within the 2-hour period: 0 to \<= 30 minutes, \> 30 to \<= 60 minutes, \>60 to \<= 90 minutes, and \>90 to \<= 120 minutes.

Time frame:
From Baseline to 3 hours after the initial BRV treatment

No measurements were reported for this outcome.

SecondaryPercentage of Participants With at Least 80% Reduction in Nonsevere Seizure Burden From Baseline to 3 Hours After the Initial BRV Treatment

Nonsevere seizure burden was defined as \<=50% seizure activity on VEEG in all 30-minute timespans. Seizure burden was measured during the Baseline Period immediately prior to BRV administration and evaluated for a 2-hour period starting 1 hour after the start of initial BRV. Timespans of 30 minutes refer to the following intervals within the 2-hour period: 0 to \<= 30 minutes, \> 30 to \<= 60 minutes, \>60 to \<= 90 minutes, and \>90 to \<= 120 minutes.

Time frame:
From Baseline to 3 hours after the initial BRV treatment

No measurements were reported for this outcome.

SecondaryPercentage of Participants With at Least 50% Reduction in Severe Seizure Burden From Baseline to 3 Hours After the Initial BRV Treatment

Severe seizure burden was defined as \>50% seizure activity on VEEG in any 30-minute timespan. Seizure burden was measured during the Baseline Period immediately prior to BRV administration and evaluated for a 2-hour period starting 1 hour after the start of initial BRV. Timespans of 30 minutes refer to the following intervals within the 2-hour period: 0 to \<= 30 minutes, \> 30 to \<= 60 minutes, \>60 to \<= 90 minutes, and \>90 to \<= 120 minutes.

Time frame:
From Baseline to 3 hours after the initial BRV treatment

No measurements were reported for this outcome.

SecondaryAbsolute Change in Average Seizure Burden Measured by Continuous Video-electroencephalography (VEEG) From Baseline to the End of the 96-hour Evaluation Period

Seizure burden was measured by continuous video-electroencephalography (VEEG). Baseline seizure burden is defined as seizure burden measured on the continuous VEEG (total electroencephalographic neonatal seizures (ENS) in minutes per hour) during a period of up to 1 hour immediately prior to the first administration of study drug.

Time frame:
From Baseline to the end of the 96-hour Evaluation Period

No measurements were reported for this outcome.

SecondaryPercentage Change in Average Seizure Burden Measured by Continuous VEEG From Baseline to the End of the 96-hour Evaluation Period

Seizure burden was measured by continuous video-electroencephalography (VEEG). Baseline seizure burden was defined as seizure burden measured on the continuous VEEG (total electroencephalographic neonatal seizures (ENS) in minutes per hour) during a period of up to 1 hour immediately prior to the first administration of study drug.

Time frame:
From Baseline to the end of the 96-hour Evaluation Period

No measurements were reported for this outcome.

SecondaryPercentage of BRV Responders at the End of the 96-hour Evaluation Period

A BRV responder was defined as a participant who achieves the following reduction in seizure burden (electroencephalographic neonatal seizures (ENS) in minutes per hour) without need for rescue medication, compared to the seizure burden measured during the Baseline Period immediately prior to BRV administration, evaluated for a 2-hour period starting 1 hour after the start of initial BRV treatment: At least 80% reduction in nonsevere seizure burden (Nonsevere seizure burden is defined as \<=50% seizure activity on VEEG in all 30-minute timespans), OR At least 50% reduction in severe seizure burden (Severe seizure burden is defined as \>50% seizure activity on VEEG in any 30-minute timespan).

Time frame:
From Baseline to the end of the 96-hour Evaluation Period

No measurements were reported for this outcome.

SecondaryPercentage of Participants Who Are Seizure-free at 24 Hours Following the Start of Initial BRV Treatment, Categorized by Subjects With Nonsevere or Severe Seizure Burden at Baseline

Seizure freedom is defined as 100 % reduction in seizure burden from Baseline.

Time frame:
From Baseline to 24 hours after the initial BRV treatment

No measurements were reported for this outcome.

SecondaryTime to Reduction in Seizure Burden for BRV Responders

A BRV responder was defined as a participant who achieves the following reduction in seizure burden (electroencephalographic neonatal seizures (ENS) in minutes per hour) without need for rescue medication, compared to the seizure burden measured during the Baseline Period immediately prior to BRV administration, evaluated for a 2-hour period starting 1 hour after the start of initial BRV treatment: At least 80% reduction in nonsevere seizure burden (Nonsevere seizure burden is defined as \<=50% seizure activity on VEEG in all 30-minute timespans), OR At least 50% reduction in severe seizure burden (Severe seizure burden is defined as \>50% seizure activity on VEEG in any 30-minute timespan).

Time frame:
From Baseline to the first timepoint when BRV responder criteria are met (up to 96-hour Evaluation Period)

No measurements were reported for this outcome.

SecondaryPercentage of Participants With Seizure Freedom at the End of the Down-Titration Period

Seizure freedom was defined as 100% reduction in seizure burden from Baseline.

Time frame:
From Baseline to the end of the Down-Titration Period (up to 97 days)

No measurements were reported for this outcome.

SecondaryPercentage of Participants With at Least 50% Reduction in Electroencephalographic Neonatal Seizures (ENS) Frequency Per Hour From Baseline to the End of the 96-hour Evaluation Period

For this study, an ENS was defined as an EEG seizure lasting for at least 10 seconds on VEEG. Baseline seizure burden was defined as seizure burden measured on the continuous VEEG (total ENS in minutes per hour) during a period of up to 1 hour immediately prior to the first administration of study drug.

Time frame:
From Baseline to the end of the 96-hour Evaluation Period

No measurements were reported for this outcome.

SecondaryPercentage of Participants Who Are Seizure-free by Time Interval Over the 96-hour Evaluation Period Following the Start of the Initial BRV Treatment

Seizure freedom was defined as 100% reduction in seizure burden from Baseline.

Time frame:
From 3 hours following the start of the initial BRV treatment to the end of the 96-hour Evaluation Period

No measurements were reported for this outcome.

SecondaryAbsolute Difference in Clinical Seizures at the End of the 24-hour Evaluation Period From Baseline for Neonates With Motor Seizures at the Time of Inclusion

Seizures was measured by continuous video-electroencephalography (VEEG).

Time frame:
From Baseline to the end of the 24-hour Evaluation Period

No measurements were reported for this outcome.

SecondaryPercent Difference in Clinical Seizures at the End of the 24-hour Evaluation Period From Baseline for Neonates With Motor Seizures at the Time of Inclusion

Seizures was measured by continuous video-electroencephalography (VEEG).

Time frame:
From Baseline to the end of the 24-hour Evaluation Period

No measurements were reported for this outcome.

SecondaryPercentage of Participants With Adverse Events (AEs) as Reported by the Investigator

An adverse event (AE) was any untoward medical occurrence in a patient or clinical investigation study participant administered a pharmaceutical product that did not necessarily have a causal relationship with this treatment.

Time frame:
Adverse Events were collected from Screening Period until the Safety Follow-Up Visit (up to Day 75)
Reported as:
Number · percentage of participants
Percentage of Participants With Adverse Events (AEs) as Reported by the Investigator
percentage of participantsExploratory CohortConfirmatory Cohort
Percentage of Participants With Adverse Events (AEs) as Reported by the Investigator55.6—

Adverse events

Collected over Adverse Events were collected from Screening Period until the Safety Follow-Up Visit (up to Day 75). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Exploratory Cohort0/9 (0%)1/9 (11.1%)5/9 (55.6%)
Most frequent serious events
Most frequent serious events
EventExploratory Cohort
ApnoeaRespiratory, thoracic and mediastinal disorders1/9
Most frequent other events
Most frequent other events
EventExploratory Cohort
AnaemiaBlood and lymphatic system disorders1/9
Dry eyeEye disorders1/9
Ammonia increasedInvestigations1/9
Liver function test abnormalInvestigations1/9
Oxygen saturation decreasedInvestigations1/9
HyperglycaemiaMetabolism and nutrition disorders1/9
HypokalaemiaMetabolism and nutrition disorders1/9

Baseline characteristics

Baseline Characteristics refer to the All Study Participants Screened Set which consisted of all study participants who had signed the Informed Consent form (ICF) and underwent the study inclusion and exclusion criteria of the current protocol. No eligible study participants were enrolled in the Confirmatory Cohorts. The study stopped prematurely due to enrolment challenges, the termination was not linked to any safety issues.

Age, Continuous
Age, Continuous(weeks)Exploratory Cohort
Mean39.2 ± 1.9
Age, Customized
Age, Customized(Participants)Exploratory Cohort
Gestational Age <37 weeks2
Gestational Age >=37 weeks7
Sex: Female, Male
Sex: Female, Male(Participants)Exploratory Cohort
Female6
Male3
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Exploratory Cohort
White8
Other/mixed1
08

Study locations

12 sites
  • N01349 204
    Leuven, Belgium
  • N01349 205
    Praha, Czechia
  • N01349 207
    Lille, France
  • N01349 206
    Paris, France
  • N01349 218
    Erlangen, Germany
  • N01349 209
    Freiburg, Germany
  • N01349 211
    Cork, Ireland
  • N01349 212
    Messina, Italy
  • N01349 213
    Parma, Italy
  • N01349 256
    Roma, Italy
  • N01349 251
    Cambridge, United Kingdom
  • N01349 216
    London, United Kingdom
09

References and documents

Publications

  • Pressler R, Boylan G, Dempsey E, Klotz KA, Krauwinkel W, Will E, Morita D, Floricel F, Elshoff JP, van den Anker J. Pharmacokinetics and safety of brivaracetam in neonates with repeated electroencephalographic seizures: A multicenter, open-label, single-arm study. Epilepsia Open. 2024 Apr;9(2):522-533. doi: 10.1002/epi4.12875. Epub 2024 Jan 11. PubMed 38049197 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe, or global development is discontinued, and 18 months after trial completion. Investigators may request access to anonymized individual patient-level data and redacted trial documents which may include: analysis-ready datasets, study protocol, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a prespecified time, typically 12 months, on a password protected portal. This plan may change if the risk of re-identifying trial participants is determined to be too high after the trial is completed; in this case and to protect participants, individual patient-level data would not be made available.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe or global development is discontinued, and 18 months after trial completion.

Access criteria: Qualified researchers may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2019 to primary completion in Sep 2020, 15 months.

Results were first posted in Jan 2024, 3 years 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 25, 2017
First posted
Oct 30, 2017
StartActual
May 7, 2019
Primary completionActual
Sep 3, 2020
CompletionActual
May 29, 2021
Results first posted
Jan 16, 2024
Last update
Apr 8, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 8, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03325439
Lead sponsor
UCB Biopharma SRL
Responsible party
Sponsor
First posted
Oct 30, 2017
Start date
May 7, 2019
Primary completion
Sep 3, 2020
Completion
May 29, 2021
Results posted
Jan 16, 2024
Last update
Apr 8, 2024

Study contacts

UCB Cares
study director · UCB (+1 844 599 2273)

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brivaracetam

Start the discussion